IAS 2023: new Gilead data support more growth for Biktarvy

24 July 2023

Californian antiviral specialist Gilead Sciences (Nasdaq: GILD) has revealed new analyses for its flagship medication Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

Presenting at the AIDS Society meeting (IAS) in Australia, the company said the data support the use of the product for a broad range of people with HIV.

Having moved past peak revenues for its breakthrough hepatitis C medicines, Gilead has successfully maintained growth momentum with Biktarvy, a powerful once-daily triplet medication with a high barrier to resistance.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK